AFT Pharmaceuticals (ASX:AFP) has today welcomed Medsafe’s decision to classify all medicines containing codeine as prescription medicines.
AFT Pharmaceutical’s Managing Director Dr Hartley Atkinson said the New Zealand medicine regulator’s decision was a good result for AFT and would increase demand for the company’s patented pain relief medicine Maxigesic as well as reduce codeine overdoses and poisonings.
Dr Atkinson added that in the 12 months after Australia rescheduled codeine containing medicines in 2018, sales of Maxigesic tablets increased by more than 50%.
Shares in AFT Pharmaceuticals (ASX:AFP) are trading 6.5 per cent higher at $3.10.
05 Feb 2020 - Computershare (ASX:CPU) has acquired Corporate Creations, US registered agent providers servicing over 14,000 corporate entities across America.
04 Sep 2019 - Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patients who completed the CelGro® tendon regeneration clinical trial showing 89 per cent of patients return to work and recreation pain-free.
23 Aug 2022 - A snapshot of the stocks on the move featuring American West Metals (ASX:AW1), Culpeo Minerals (ASX:CPO), Strike Energy (ASX:STX), Warrego Energy (ASX:WGO).
29 Jan 2021 - Shares in BlueScope Steel (ASX:BSL) are on the rise this morning, after it announced that it expects earnings before interest and tax for the first half of the 2021 financial year to be around $530 million.
14 Jul 2023 - A snapshot of the stocks on the move, featuring Neuren Pharmaceuticals (ASX:NEU), Green Technology Metals (ASX:GT1) and One Click Group (ASX:1CG).
07 Apr 2021 - UAS (unmanned aerial systems) technology developer DroneShield (ASX:DRO) has secured another government contract to provide drone security solutions to one of the Five Eyes countries (United States, Canada, Australia, the United Kingdom, and New Zealand).
24 Jun 2020 - Freedom Foods Group (ASX:FNP) today announced that the Managing Director and CEO, Rory Macleod, is on leave pending a further announcement that is expected to be made early next week.
26 Nov 2020 - Gentrack Group Limited (ASX:GTK) report results for the year show underlying EBITDA of $12.1 million, down 51 per cent on FY19, off the back of lower FY20 revenues coming in at $100.5 million, a 10 per cent decrease on FY19.
